Detalhe da pesquisa
1.
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
N Engl J Med
; 366(8): 707-14, 2012 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-22356324
2.
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
N Engl J Med
; 366(3): 207-15, 2012 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22256804
3.
Analysis of dermatologic events in vemurafenib-treated patients with melanoma.
Oncologist
; 18(3): 314-22, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23457002
4.
A case of laryngeal carcinoma in a young adult with dyskeratosis congenita.
Int J Clin Oncol
; 15(4): 428-32, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20198396
5.
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
J Clin Oncol
; 38(1): 1-10, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31682550
6.
Inhibition of BCL2 expression and activity increases H460 sensitivity to the growth inhibitory effects of polyphenon E.
J Exp Ther Oncol
; 8(2): 129-44, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-20192119
7.
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
J Clin Oncol
; 37(4): 318-327, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30557521
8.
(-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells.
Carcinogenesis
; 29(10): 1986-93, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18586691
9.
Comparing genetic ancestry and self-described race in african americans born in the United States and in Africa.
Cancer Epidemiol Biomarkers Prev
; 17(6): 1329-38, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18559547
10.
A case of primary Hodgkin's lymphoma of the parotid gland.
Auris Nasus Larynx
; 35(3): 440-2, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17983719
11.
Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
Clin Cancer Res
; 12(11 Pt 1): 3478-84, 2006 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16740773
12.
17HSD 2 may be higher in African-American breast cancer and is associated with estrogen receptor-negative tumors.
Cancer Genomics Proteomics
; 4(5): 341-8, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17993718
13.
EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells.
J Exp Ther Oncol
; 5(1): 69-78, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16416603
14.
Cyclin D1 overexpression is associated with estrogen receptor expression in Caucasian but not African-American breast cancer.
Anticancer Res
; 25(1A): 273-81, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-15816548
15.
Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines.
Clin Cancer Res
; 8(3): 893-903, 2002 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-11895924
16.
A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma.
Pharmacol Res Perspect
; 3(2): e00113, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25729580
17.
Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus.
Cancer Prev Res (Phila)
; 8(12): 1131-7, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26471236
18.
Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells.
J Exp Ther Oncol
; 3(2): 83-94, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-12822514
19.
The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.
J Clin Pharmacol
; 54(4): 368-74, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24374975
20.
Somatic evolution of head and neck cancer - biological robustness and latent vulnerability.
Mol Oncol
; 7(1): 14-28, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23168041